Julianne Gee is an epidemiologist at the Centers for Disease Control and Prevention (CDC) in the United States, currently serving as the Deputy Team Lead of the Vaccine Safety Team on the CDC’s COVID-19 Vaccine Task Force. She has been in this role since September 2020, and has assisted in the planning and implementation of many COVID-19 vaccine safety activities.
Ms Gee authored CDC’s first publication on COVID-19 vaccine safety, describing the safety profile of mRNA vaccines during the first month of the COVID-19 vaccination programme in the United States, and has co-authored numerous COVID-19 vaccination publications. Her responsibilities have recently expanded to serve as a senior technical advisor to the Global Immunization Safety Team, providing subject matter expertise on vaccine safety monitoring methods, including active and passive surveillance systems.
Before the COVID-19 response, Ms Gee had been working in CDC’s Immunization Safety Office with the Vaccine Safety Datalink Project, focusing her work on HPV vaccine safety.
Michael Gold is a paediatric allergist and immunologist with conjoint positions as a senior consultant based in the Department of Allergy and Clinical Immunology, Women’s and Children’s Health Network, and a clinical academic at the University of Adelaide, Australia.
Professor Gold has a research and clinical interest in vaccine safety. He was appointed to the World Health Organization (WHO) Global Advisory Committee for Vaccine Safety in 2010, and is a committee member of the Vaccine Safety Investigation Group (VSIG) of the Australian Therapeutic Goods Administration and of the AusVaxSafety Expert Advisory Group for Active Vaccine Surveillance.
He has been awarded a number of Australian national research grants as a principal investigator for projects that have researched novel methods of safety surveillance including data linkage and m-Health. He has contributed to a number of key WHO guidelines which include the global Adverse Event Following Immunisation surveillance manual, the WHO guideline on causality assessment, a guideline for programme managers on immunisation stress related responses, and the global manual for COVID vaccine safety surveillance. He is also chairing a working group which is reformulating the Brighton Collaboration case definition for anaphylaxis.
Professor Gold has participated in numerous WHO-organised training courses to strengthen adverse event surveillance and causality assessment systems in Low and Middle Income Countries and is currently a consultant to the WHO South East Asian Region, facilitating the implementation of COVID vaccine pharmacovigilance. He has contributed to the Vaccines for Africa (VACFA) initiative through research collaborations and presentations at the annual vaccinology course based at the University of Cape Town.
Helen Petousis-Harris is a vaccinologist, Associate Professor in the Department of General Practice and Primary Health Care at the University of Auckland, and the Director of the Vaccine Datalink and Research Group.
Since 1998, she has been involved in immunisation-related research in New Zealand including clinical, social science, epidemiological, and health systems research. Her main research areas are vaccine safety and vaccine effectiveness, and currently she is co-leading the Global Vaccine Data Network, a multinational consortium dedicated to collaboration in vaccine safety studies. She was previously the chair of the WHO Global Advisory Committee on Vaccine Safety (GACVS) and is currently an elected member of the international Brighton Collaboration Science Board.
She is a media spokesperson on vaccines and vaccination, a science communicator, and teaches undergraduate and post graduate courses.